Barclays raised the firm’s price target on Insulet (PODD) to $316 from $301 and keeps an Overweight rating on the shares. The firm views the company’s Q3 report as “impressive.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet Corporation Reports Strong Q3 2025 Results
- Insulet’s Earnings Call: Record Growth and Strategic Expansion
- Insulet’s Strong Sales and Strategic Growth Drive Buy Rating
- Insulet price target raised to $400 from $375 at Jefferies
- Insulet’s Strong Financial Performance and Growth Prospects Earn Buy Rating from Analyst